Amplified Sciences

Executive Summary

Amplified Sciences is a clinical-stage diagnostics company headquartered in West Lafayette, Indiana, dedicated to developing ultra-sensitive diagnostic tests for early detection and monitoring of challenging diseases, with an initial focus on pancreatic cancer. Founded in 2019, the company leverages its proprietary universal optical reporter platform technology, which provides extreme sensitivity to detect disease biomarkers at very low concentrations. This platform has the potential to significantly improve outcomes by enabling earlier diagnosis and risk stratification of pancreatic cancer, a disease where late detection leads to poor survival rates. The company is currently advancing its lead test through clinical development, aiming to address a critical unmet need in oncology diagnostics. While Amplified Sciences remains in the preclinical/clinical validation phase, its platform technology has broad applicability beyond pancreatic cancer, including other solid tumors and chronic diseases. The company has not yet disclosed funding rounds or valuation, suggesting it may be operating in stealth or early funding stages. However, the growing demand for non-invasive, highly sensitive diagnostic tools positions Amplified Sciences for potential partnerships or commercial interest. Key upcoming milestones include completing proof-of-concept studies, securing Series A financing, and initiating discussions with strategic partners for co-development or licensing. The company's success will depend on clinical validation results and its ability to navigate regulatory pathways.

Upcoming Catalysts (preview)

• Q2 2026Clinical proof-of-concept data readout for pancreatic cancer test70% success
• Q3 2026Strategic partnership or licensing deal for platform technology50% success
• Q4 2026Series A financing round closing60% success